ThomasMHabermannMD

PubMed

• Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
  Suheil Albert Atallah-Yunes, Thomas M Habermann, Arushi Khurana> ;British Journal of Haematology. 2024 Apr 5
• Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy.
  Jessica F Burlile, Kelsey M Frechette, William G Breen, Steven R Hwang, Alexandra S Higgins, Adrienne N Nedved, William S Harmsen, Sydney D Pulsipher, Thomas E Witzig,...> ;Blood Advances. 2024 Mar 12
• Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments.
  Jordan E Krull, Kerstin Wenzl, Melissa A Hopper, Michelle K Manske, Vivekananda Sarangi, Matthew J Maurer, Melissa C Larson, Patrizia Mondello, ZhiZhang Yang, Joseph P...> ;Cell Reports. Medicine. 2024 Mar 19
• Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
  Tun, A., Bisneto, J., Wang, Y., Maliske, S., Micallef, I., Inwards, D., Habermann, T., Porrata, L., Paludo, J., Rosenthal, A., Kharfan-Dabaja, M., Ansell, S., Nowakows...> ;Haematologica. 2024 Jan 18
• 1 citations
  Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
  Steiner, R., Hwang, S., Khurana, A., Habermann, T., Epperla, N., Annunzio, K., Allen, P., Baird, K., Paulino, D., Alderuccio, J., Lossos, I., David, K., Evens, A., Pan...> ;Blood Advances. 2023 Dec 26
• Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzu...
  Matthew J Maurer, Carla Casulo, Melissa C Larson, Thomas M Habermann, Izidore S Lossos, Yucai Wang, Loretta J Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin...> ;Haematologica. 2023 Nov 30
• 1 citations
  Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
  Allison M Bock, Jennifer J Gile, Melissa C Larson, Kittika Poonsombudlert, Reema K Tawfiq, Seth Maliske, Matthew J Maurer, Brian F Kabat, Jonas Paludo, David J Inwards...> ;Blood Cancer Journal. 2023 Nov 13
• Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data.
  Priyanka A Pophali, Lindsay M Morton, Susan K Parsons, David Hodgson, Gita Thanarajasingam, Carrie Thompson, Thomas M Habermann, Kerry J Savage> ;Ejhaem. 2023 Nov 1
• Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
  Colleen A Ramsower, Allison Rosenthal, Ryan S Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B Cohen, Thomas Habermann...> ;British Journal of Haematology. 2024 Jan 1
• Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia.
  Saurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, Morie A Gertz, Michelle Mauermann, Thomas E Witzig, Patrick Johnston, Robert A Kyle, Rebecca L King, Thomas M Habe...> ;Leukemia & Lymphoma. 2023 Jun 10
• Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas.
  Melissa A Hopper, Kerstin Wenzl, Keenan T Hartert, Jordan E Krull, Abigail R Dropik, Joseph P Novak, Michelle K Manske, MaKayla R Serres, Vivekananda Sarangi, Melissa ...> ;Hematological Oncology. 2023 Oct 1
• 4 citations
  Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy.
  Bezerra, E., Iqbal, M., Munoz, J., Khurana, A., Wang, Y., Maurer, M., Bansal, R., Hathcock, M., Bennani, N., Murthy, H., Rosenthal, A., Paludo, J., Villasboas, J., Joh...> ;Blood Advances. 2023 Apr 25
• 1 citations
  Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.
  Yucai Wang, Aasiya Matin, David J Inwards, Thomas M Habermann, Ivana Micallef, Patrick B Johnston, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenth...> ;Hemasphere. 2023 Apr 1
• 1 citations
  Treatment intensification might not improve survival in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: A retrospective, multicent...
  Vanja Zeremski, Ellen D McPhail, Thomas M Habermann, Francesca Schieppati, Niklas Gebauer, Theodoros P Vassilakopoulos, Dimitrios Mougiakakos> ;Hematological Oncology. 2023 Oct 1
• 2 citations
  Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
  Juan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, Melissa C Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M Habermann, Peter Martin, Jennifer R Chapman, Chri...> ;Blood. 2023 Apr 13
• Induction treatment in high-grade B-cell lymphoma with a concurrentandand/orrearrangement: a systematic review and meta-analysis.
  Vanja Zeremski, Siegfried Kropf, Michael Koehler, Niklas Gebauer, Ellen D McPhail, Thomas Habermann, Francesca Schieppati, Dimitrios Mougiakakos> ;Frontiers in Oncology. 2023 Jan 1
• End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
  Karan L Chohan, Jason R Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Rosenthal, Han W Tun, Bradford S Hoppe, Patrick B Johnston, Ivana N Micallef, Thomas M Hab...> ;Haematologica. 2023 Jun 1
• 3 citations
  Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
  Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N Gerson, Stefan K Barta, Max J Gordon, Alexey V Danilov, Natalie S Grover, Stephanie Mathews, Made...> ;Blood Advances. 2023 Jun 13
• 5 citations
  Central nervous system involvement by mantle cell lymphoma.
  Nicole McLaughlin, Yucai Wang, Thomas Witzig, Jose Villasboas, Thomas Habermann, David Inwards, Nora Bennani, Gita Thanarajasingam, Grzegorz Nowakowski, Luis Porrata, ...> ;Leukemia & Lymphoma. 2023 Feb 1
• 1 citations
  Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
  Sanjal H Desai, Raphael Mwangi, Alexandra N Smith, Matthew J Maurer, Umar Farooq, Rebecca L King, James R Cerhan, Andrew L Feldman, Thomas M Habermann, Carrie A Thomps...> ;Hematological Oncology. 2023 Feb 1
• 4 citations
  Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
  Sonja I Berndt, Joseph Vijai, Yolanda Benavente, Nicola J Camp, Alexandra Nieters, Zhaoming Wang, Karin E Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, ...> ;Leukemia. 2022 Dec 1
• 1 citations
  High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
  Darragh F O'Donoghue, Huong L Truong, Heidi D Finnes, Jennifer S McDonald, Heather P May, Stephen M Ansell, N Nora Bennani, Thomas M Habermann, David J Inwards, Patric...> ;JCO Oncology Practice. 2022 Dec 1
• MCL-027 Prognostic Role of Event-free Survival at 24 Months (EFS24) in Newly Diagnosed Mantle Cell Lymphoma (MCL).
  Yucai Wang, Melissa C Larson, Matthew J Maurer, Brian K Link, Umar Farooq, Thomas E Witzig, Thomas M Habermann, James R Cerhan, Grzegorz S Nowakowski> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis.
  Sanjal H Desai, Raphael Mwangi, Rebecca L King, Matthew J Maurer, James R Cerhan, Andrew L Feldman, Umar Farooq, Eric Mou, Thomas M Habermann, Carrie A Thompson, Yucai...> ;Blood Advances. 2022 Dec 27
• 7 citations
  Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.
  Juan Pablo Alderuccio, Isildinha M Reis, Thomas M Habermann, Brian K Link, Catherine Thieblemont, Annarita Conconi, Melissa C Larson, Luciano Cascione, Wei Zhao, James...> ;American Journal of Hematology. 2022 Dec 1
• Join now to see all

Journal Articles

• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Publisher Correction: Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes  
  Thomas M Habermann, Scott J Rodig, Rameen Beroukhim, Jeremiah A Wala, Andrew L Feldman, Todd R Golub, Margaret A Shipp, Nature
• Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome for Patients with Diffuse Large B-cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials  
  Thomas Habermann, MD, Annals of Oncology

Abstracts/Posters

• Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An Internation...
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease? 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all